Literature DB >> 15331450

Re-establishment of VWF-dependent Weibel-Palade bodies in VWD endothelial cells.

Sandra L Haberichter1, Elizabeth P Merricks, Scot A Fahs, Pamela A Christopherson, Timothy C Nichols, Robert R Montgomery.   

Abstract

Type 3 von Willebrand disease (VWD) is a severe hemorrhagic defect in humans. We now identify the homozygous mutation in the Chapel Hill strain of canine type 3 VWD that results in premature termination of von Willebrand factor (VWF) protein synthesis. We cultured endothelium from VWD and normal dogs to study intracellular VWF trafficking and Weibel-Palade body formation. Weibel-Palade bodies could not be identified in the canine VWD aortic endothelial cells (VWD-AECs) by P-selectin, VWFpp, or VWF immunostaining and confocal microscopy. We demonstrate the reestablishment of Weibel-Palade bodies that recruit endogenous P-selectin by expressing wild-type VWF in VWD-AECs. Expression of mutant VWF proteins confirmed that VWF multimerization is not necessary for Weibel-Palade body creation. Although the VWF propeptide is required for the formation of Weibel-Palade bodies, it cannot independently induce the formation of the granule. These VWF-null endothelial cells provide a unique opportunity to examine the biogenesis of Weibel-Palade bodies in endothelium from a canine model of type 3 VWD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15331450      PMCID: PMC3938105          DOI: 10.1182/blood-2004-02-0464

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  47 in total

Review 1.  von Willebrand disease: a common pediatric disorder.

Authors:  R R Montgomery; P A Kroner
Journal:  Pediatr Ann       Date:  2001-09       Impact factor: 1.132

2.  von Willebrand factor storage and multimerization: 2 independent intracellular processes.

Authors:  S L Haberichter; S A Fahs; R R Montgomery
Journal:  Blood       Date:  2000-09-01       Impact factor: 22.113

Review 3.  Impact, diagnosis and treatment of von Willebrand disease.

Authors:  J E Sadler; P M Mannucci; E Berntorp; N Bochkov; V Boulyjenkov; D Ginsburg; D Meyer; I Peake; F Rodeghiero; A Srivastava
Journal:  Thromb Haemost       Date:  2000-08       Impact factor: 5.249

4.  Defect in regulated secretion of P-selectin affects leukocyte recruitment in von Willebrand factor-deficient mice.

Authors:  C V Denis; P André; S Saffaripour; D D Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-06       Impact factor: 11.205

5.  Mutation causing von Willebrand's disease in Scottish Terriers.

Authors:  P J Venta; J Li; V Yuzbasiyan-Gurkan; G J Brewer; W D Schall
Journal:  J Vet Intern Med       Date:  2000 Jan-Feb       Impact factor: 3.333

6.  Assembly of multimeric von Willebrand factor directs sorting of P-selectin.

Authors:  C Hop; A Guilliatt; M Daly; H P de Leeuw; H J Brinkman; I R Peake; J A van Mourik; H Pannekoek
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-07       Impact factor: 8.311

7.  Genetic induction of a releasable pool of factor VIII in human endothelial cells.

Authors:  J B Rosenberg; J S Greengard; R R Montgomery
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-12       Impact factor: 8.311

Review 8.  Biogenesis and exocytosis of Weibel-Palade bodies.

Authors:  Jan A van Mourik; Thalia Romani de Wit; Jan Voorberg
Journal:  Histochem Cell Biol       Date:  2002-01-19       Impact factor: 4.304

9.  P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface.

Authors:  Arnoldo Padilla; Joel L Moake; Aubrey Bernardo; Chalmette Ball; Yongtao Wang; Maneesh Arya; Leticia Nolasco; Nancy Turner; Michael C Berndt; Bahman Anvari; José A López; Jing-Fei Dong
Journal:  Blood       Date:  2003-11-20       Impact factor: 22.113

10.  Analysis of intracellular storage and regulated secretion of 3 von Willebrand disease-causing variants of von Willebrand factor.

Authors:  Grégoire Michaux; Lindsay J Hewlett; Sarah L Messenger; Anne C Goodeve; Ian R Peake; Martina E Daly; Daniel F Cutler
Journal:  Blood       Date:  2003-06-05       Impact factor: 22.113

View more
  22 in total

1.  Phase II prospective open-label trial of recombinant interleukin-11 in women with mild von Willebrand disease and refractory menorrhagia.

Authors:  Margaret V Ragni; Rachel C Jankowitz; Kristen Jaworski; Elizabeth P Merricks; Mark T Kloos; Timothy C Nichols
Journal:  Thromb Haemost       Date:  2011-08-11       Impact factor: 5.249

2.  The mutation N528S in the von Willebrand factor (VWF) propeptide causes defective multimerization and storage of VWF.

Authors:  Sandra L Haberichter; Ulrich Budde; Tobias Obser; Sonja Schneppenheim; Cornelia Wermes; Reinhard Schneppenheim
Journal:  Blood       Date:  2010-03-24       Impact factor: 22.113

Review 3.  Regulation of cellular communication by signaling microdomains in the blood vessel wall.

Authors:  Marie Billaud; Alexander W Lohman; Scott R Johnstone; Lauren A Biwer; Stephanie Mutchler; Brant E Isakson
Journal:  Pharmacol Rev       Date:  2014-03-26       Impact factor: 25.468

4.  Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage.

Authors:  Paula M Jacobi; Joan Cox Gill; Veronica H Flood; David A Jakab; Kenneth D Friedman; Sandra L Haberichter
Journal:  Blood       Date:  2012-03-19       Impact factor: 22.113

5.  Biogenesis of Weibel-Palade bodies in von Willebrand's disease variants with impaired von Willebrand factor intrachain or interchain disulfide bond formation.

Authors:  Jiong-Wei Wang; Dafna J Groeneveld; Guy Cosemans; Richard J Dirven; Karine M Valentijn; Jan Voorberg; Pieter H Reitsma; Jeroen Eikenboom
Journal:  Haematologica       Date:  2011-12-29       Impact factor: 9.941

6.  Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies.

Authors:  Qizhen Shi; David A Wilcox; Scot A Fahs; Hartmut Weiler; Clive W Wells; Brian C Cooley; Drashti Desai; Patricia A Morateck; Jack Gorski; Robert R Montgomery
Journal:  J Clin Invest       Date:  2006-07       Impact factor: 14.808

Review 7.  Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.

Authors:  Timothy C Nichols; Aaron M Dillow; Helen W G Franck; Elizabeth P Merricks; Robin A Raymer; Dwight A Bellinger; Valder R Arruda; Katherine A High
Journal:  ILAR J       Date:  2009

8.  Molecular requirements for sorting of the chemokine interleukin-8/CXCL8 to endothelial Weibel-Palade bodies.

Authors:  Johanna Hol; Axel M Küchler; Finn-Eirik Johansen; Bjørn Dalhus; Guttorm Haraldsen; Inger Oynebråten
Journal:  J Biol Chem       Date:  2009-07-03       Impact factor: 5.157

9.  von Willebrand factor propeptide: biology and clinical utility.

Authors:  Sandra L Haberichter
Journal:  Blood       Date:  2015-07-27       Impact factor: 22.113

10.  A phase II prospective open-label escalating dose trial of recombinant interleukin-11 in mild von Willebrand disease.

Authors:  M V Ragni; R C Jankowitz; H L Chapman; E P Merricks; M T Kloos; A M Dillow; T C Nichols
Journal:  Haemophilia       Date:  2008-08-01       Impact factor: 4.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.